Compare ALKS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKS | PRAX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.6B |
| IPO Year | 2012 | 2020 |
| Metric | ALKS | PRAX |
|---|---|---|
| Price | $43.72 | $300.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | $43.43 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 1.3M | 296.5K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,475,899,000.00 | N/A |
| Revenue This Year | $24.26 | N/A |
| Revenue Next Year | $4.47 | $7,758.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.99 | $41.78 |
| 52 Week High | $55.67 | $392.70 |
| Indicator | ALKS | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.05 | 30.44 |
| Support Level | $36.25 | $290.53 |
| Resistance Level | $51.25 | $328.24 |
| Average True Range (ATR) | 1.39 | 14.50 |
| MACD | -0.10 | -6.89 |
| Stochastic Oscillator | 5.25 | 5.68 |
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.